Search for a command to run...
Panacea Biotec Ltd. shows some signs of growth but struggles significantly with profitability and valuation metrics compared to its peers. Companies like Cipla and Sun Pharmaceutical stand out as leaders in profitability, while Panacea remains a high-risk player due to negative earnings and high valuation ratios. Overall, the pharmaceutical sector has strong performers but also some financially weak companies that should be approached with caution.
Stocks | CMP | Market Cap | P/E | ROCE (%) | Debt/Equity |
---|---|---|---|---|---|
PANACEABIO | ₹416.80 | ₹2,552.93Cr | -167.63 | 0.59% | 0.02 |
SUNPHARMA | ₹1,563.35 | ₹3,75,099.26Cr | 87.59 | 17.60% | 0.04 |
DIVISLAB | ₹6,091.05 | ₹1,61,698.50Cr | 73.20 | 16.46% | - |
CIPLA | ₹1,587.60 | ₹1,28,217.27Cr | 23.73 | 22.77% | 0.01 |
TORNTPHARM | ₹3,581.55 | ₹1,21,215.77Cr | 61.53 | 24.28% | 0.57 |
DRREDDY | ₹1,280.30 | ₹1,06,835.27Cr | 15.50 | 26.86% | 0.07 |
MANKIND | ₹2,518.95 | ₹1,03,926.59Cr | 55.18 | 28.38% | 0.02 |